An official website of the United States government
Home
Name
Leuprolide Acetate
Alternate Names
Abbott-43818
Carcinil
Eligard
Leuprolide
Leuprorelin
Lupron
Lupron Depot
Lupron TAP
TAP-144
Viadur
Abbreviations
None
Category
Hormones and hormonal mechanisms
Subcategory
Gonadotropin-releasing hormone agonist
NSC Number
377526
Primary Site
Histology
None
Remarks
December 2016 Update: Lupron as ovarian suppressor in pre-menopausal breast cancer has been approved by the FDA per NCI. Beginning with cases diagnosed 1/1/2017 forward, code as hormone therapy.
Lupron is a gonadotropin-releasing hormone analogue. FDA approved its use on prostate cancer and should be coded as hormone therapy.
FOR BREAST CASES DIAGNOSED 1/1/2017 FORWARD: Code as hormone treatment
FOR BREAST CASES DIAGNOSED PRIOR TO 1/1/2017:
The effectiveness of Lupron on patients with breast cancer was being studied in one clinical trial. This trial was looking at extended endocrine therapy for pre-menopausal women with breast cancer. This trial is looking at the drug combination of letrozole and leuprolide for women who have taken Tamoxifen for at least 4-5 years. This drug combination is used in the treatment for metastatic breast cancer and is sometimes used for treatment of early stage breast cancer. However, as of early December 2016 it has not been accepted as a standard of care treatment and had not yet received FDA approval for treatment of breast cancer. While it may not have received FDA approval, it can be used "off label" for other conditions. Lupron should be coded as "Other Therapy" until such time that it receives FDA approval.
Lupron is a gonadotropin-releasing hormone analogue. FDA approved its use on prostate cancer and should be coded as hormone therapy.
FOR BREAST CASES DIAGNOSED 1/1/2017 FORWARD: Code as hormone treatment
FOR BREAST CASES DIAGNOSED PRIOR TO 1/1/2017:
The effectiveness of Lupron on patients with breast cancer was being studied in one clinical trial. This trial was looking at extended endocrine therapy for pre-menopausal women with breast cancer. This trial is looking at the drug combination of letrozole and leuprolide for women who have taken Tamoxifen for at least 4-5 years. This drug combination is used in the treatment for metastatic breast cancer and is sometimes used for treatment of early stage breast cancer. However, as of early December 2016 it has not been accepted as a standard of care treatment and had not yet received FDA approval for treatment of breast cancer. While it may not have received FDA approval, it can be used "off label" for other conditions. Lupron should be coded as "Other Therapy" until such time that it receives FDA approval.
Coding
Please see remarks for additional information
